Drug Metabolism, Prodrugs and Pharmacokinetics
CSIR NET medicinal chemistry: phase I and II metabolism, cytochrome P450, prodrugs and soft drugs, half-life, clearance and bioavailability.
- 16 min
On this page · 14 sections
Prerequisites
- Oxidation and reduction of organic functional groups: Oxidations and Reductions.
- First-order kinetics, half-lives and integrated rate laws: Rate Laws and Temperature Dependence.
- Lipophilicity, \( pK_a \) and ionisation, used throughout: Physicochemical Properties, SAR and QSAR.
- Iron porphyrin chemistry behind P450: Porphyrins and Oxygen Transport.
- Enantiomers, racemates and their analysis: Stereogenicity, Chirality and Configuration.
The Hook: The Molecule That Is Not the Drug
ADME in One Line Each
| Step | What governs it |
|---|---|
| Absorption | solubility, \( \log D \) at the relevant pH, permeability, transporters, first-pass metabolism |
| Distribution | lipophilicity, plasma-protein binding, tissue partitioning, ability to cross the blood–brain barrier |
| Metabolism | phase I functionalisation, phase II conjugation (chiefly in the liver) |
| Excretion | renal (favours small, polar, ionised species), biliary (favours larger conjugates) |
The thread running through all four is polarity: absorption needs a molecule lipophilic enough to cross membranes, and excretion needs one polar enough not to be reabsorbed. Metabolism is the machinery that converts the first into the second.
Phase I: Functionalisation
Phase I introduces or unmasks a polar group (OH, NH\(_2\), SH, COOH) — usually by oxidation, sometimes by reduction or hydrolysis.
Cytochrome P450
A haem-thiolate monooxygenase (cysteine thiolate as the proximal ligand) carrying out
$$\mathrm{RH} + \mathrm{O_2} + \mathrm{NADPH} + \mathrm{H^+} \longrightarrow \mathrm{ROH} + \mathrm{H_2O} + \mathrm{NADP^+}$$One oxygen atom ends up in the substrate and one in water — hence monooxygenase. The reactive intermediate is a high-valent iron–oxo species; hydroxylation of an unactivated C–H is generally described as hydrogen-atom abstraction followed by rapid oxygen rebound.
| P450 transformation | Example substrate type |
|---|---|
| Aliphatic hydroxylation (often at the ω or ω−1 position) | alkyl chains |
| Aromatic hydroxylation via an arene oxide | benzene rings (NIH shift of the migrating hydrogen) |
| N-, O- and S-dealkylation (hydroxylation at the carbon α to the heteroatom, then collapse to the carbonyl compound) | tertiary amines, methyl ethers, thioethers |
| N- and S-oxidation | amines (also by flavin monooxygenases), sulfides → sulfoxides → sulfones |
| Oxidative deamination | primary amines |
| Epoxidation | alkenes, polycyclic aromatics |
Human drug metabolism is dominated by a handful of isoforms, of which CYP3A4 handles the largest share of marketed drugs; CYP2D6 is notable for genetic polymorphism, so the same exposure gives very different metabolite profiles in different people. Inhibition of an isoform (a classic example is the inhibition of intestinal CYP3A4 by components of grapefruit juice) raises the exposure of its substrates; induction (rifampicin, carbamazepine and St John’s wort are standard examples of inducers) lowers it. This is the chemical basis of most metabolic drug–drug interactions.
Non-P450 phase I
| Enzyme | Reaction |
|---|---|
| Esterases and amidases | hydrolysis of esters (fast) and amides (slower) — the basis of ester prodrugs |
| Alcohol and aldehyde dehydrogenases | R-CH\(_2\)OH → RCHO → RCOOH |
| Monoamine oxidase | oxidative deamination of amines |
| Xanthine oxidase, aldehyde oxidase | oxidation of azaheterocycles |
| Reductases (including gut flora) | nitro → amine; azo → two amines; carbonyl → alcohol |
Phase II: Conjugation
Phase II attaches a large polar (often anionic) group, usually to a phase I product, making the molecule a substrate for active excretion.
| Conjugation | Cofactor / donor | Typical acceptor |
|---|---|---|
| Glucuronidation (UGT) | UDP-glucuronic acid | OH, COOH, NH, SH — the commonest route |
| Sulfation (SULT) | PAPS (3′-phosphoadenosine-5′-phosphosulfate) | phenols, alcohols, amines; high affinity but easily saturated |
| Glutathione conjugation (GST) | glutathione (γ-Glu-Cys-Gly) | electrophiles: epoxides, quinones, Michael acceptors, alkyl halides; leads to mercapturic acids |
| Acetylation (NAT) | acetyl-CoA | aromatic amines, hydrazines; polymorphic (fast/slow acetylators) |
| Methylation (MT) | S-adenosylmethionine | catechols (COMT), thiols, some amines |
| Amino-acid conjugation | glycine, glutamine | carboxylic acids (e.g. benzoate → hippurate) |
graph TD
A["Lipophilic drug"] --> B["Phase I
P450 oxidation, reduction, hydrolysis"]
A --> C["Phase II directly
if a handle already exists"]
B --> D["Metabolite with OH / NH2 / COOH"]
D --> C
C --> E["Glucuronide, sulfate, GSH adduct,
acetyl or methyl derivative"]
E --> F["Renal or biliary excretion"]
B --> G["Reactive electrophile
(epoxide, quinone imine)"]
G --> H["Glutathione capture"]
G --> I["Covalent binding: toxicity"]Designing With and Against Metabolism
Blocking metabolism
- Put fluorine (or another blocking group) at the site of hydroxylation.
- Replace a labile ester by an amide or a non-hydrolysable isostere.
- Add steric hindrance near the point of attack, or remove the benzylic/allylic C–H that invites it.
- Remove the catechol that COMT would methylate, or the phenol that is sulfated on first pass.
Exploiting it: prodrugs
A prodrug is inactive (or much less active) as administered and releases the active species by a chemical or enzymatic step in vivo.
| Purpose | Strategy | Example |
|---|---|---|
| Improve absorption of an acid | ester, hydrolysed by esterases | enalapril, an ethyl ester, releases the diacid enalaprilat |
| Improve aqueous solubility for injection | phosphate or hemisuccinate ester | phosphate esters of poorly soluble parent drugs |
| Cross a barrier | use a transporter | levodopa is carried into the brain by an amino-acid transporter and decarboxylated to dopamine, which cannot cross on its own |
| Deliver to a site | release by local enzymes or flora | sulfasalazine is cleaved by colonic bacterial azoreductase to 5-aminosalicylate |
| Activate only in the target | target-specific enzymatic step | acyclovir is phosphorylated by a viral thymidine kinase; omeprazole cyclises only in strong acid |
| Mask taste or irritancy | ester or amide | several paediatric ester formulations |
A soft drug is the mirror image: an active compound designed to be rapidly and predictably deactivated by hydrolysis once it has acted, limiting systemic exposure. Short-acting esterase-labile agents used in anaesthesia and critical care follow this design.
Chirality
Enantiomers are not equivalent in a chiral body: they differ in potency at the target, in off-target effects and in metabolism. Standard teaching examples are the aryloxypropanolamine β-blockers (the \( S \) enantiomer of propranolol carries most of the β-blocking activity), the 2-arylpropanoic acid anti-inflammatories (the \( S \) enantiomer is the active one, and \( R \to S \) inversion occurs in vivo for some members), and thalidomide, whose enantiomers differ pharmacologically but interconvert under physiological conditions — which is why making a single enantiomer would not, by itself, have solved the problem. Measuring enantiomeric excess is covered in Enantiomeric and Diastereomeric Excess.
Pharmacokinetics: the Minimum Arithmetic
Treat elimination as first order in plasma concentration \( C \):
$$C = C_0e^{-kt}, \qquad t_{1/2} = \frac{\ln 2}{k} = \frac{0.693}{k}$$| Quantity | Definition | Relation |
|---|---|---|
| Volume of distribution \( V_d \) | apparent volume containing the dose at the plasma concentration | \( V_d = \text{dose}/C_0 \) |
| Clearance CL | plasma volume cleared per unit time | \( \mathrm{CL} = kV_d \) |
| AUC | area under the concentration–time curve | \( \mathrm{AUC} = FD/\mathrm{CL} \) |
| Bioavailability \( F \) | fraction of the dose reaching systemic circulation unchanged | \( F = (\mathrm{AUC}_{\text{oral}}/D_{\text{oral}})\big/(\mathrm{AUC}_{\text{iv}}/D_{\text{iv}}) \) |
A large \( V_d \) means extensive tissue partitioning, not a large body; it can far exceed total body water for very lipophilic bases. \( F < 1 \) for an oral dose because of incomplete absorption and first-pass metabolism in gut wall and liver.
Repeated dosing. With a dosing interval \( \tau \), the fraction of steady state reached after \( n \) intervals is \( 1 - 2^{-n\tau/t_{1/2}} \); dosing every half-life gives 50%, 75%, 87.5%, 93.75%… so steady state is effectively reached after about 4–5 half-lives, whatever the dose. A loading dose \( = V_d \times C_{\text{target}} \) short-circuits that wait; the maintenance rate \( = \mathrm{CL} \times C_{\text{target}} \) sustains it.
Zero-order (saturated) elimination breaks all of this: when the metabolising enzyme is saturated, a constant amount is removed per unit time, the half-life is no longer constant, and exposure rises disproportionately with dose. Ethanol is the standard example; the general description is Michaelis–Menten elimination, which is first order at \( C \ll K_M \) and zero order at \( C \gg K_M \).
Memory Tricks
Don’t Confuse
| This | vs | That |
|---|---|---|
| Phase I (functionalisation) | Phase II (conjugation) — a conjugation is never “phase I”, even if it comes first | |
| Prodrug (activated in vivo) | Soft drug (deactivated in vivo) | |
| \( V_d \) (apparent, can exceed body volume) | A real anatomical volume | |
| Clearance (volume per time) | Elimination rate (amount per time) | |
| First-pass metabolism (lowers \( F \)) | Poor absorption (also lowers \( F \), different cause) | |
| First-order elimination (constant \( t_{1/2} \)) | Zero-order/saturated (constant amount per time) | |
| Enzyme induction (more enzyme, lower exposure) | Enzyme inhibition (less activity, higher exposure) | |
| Glucuronidation (UDP-glucuronic acid) | Sulfation (PAPS) |
Common Mistakes
Practice
All questions below are original practice questions written for this page. They are not from any CSIR NET paper.
Level 1: Foundation
- Which cofactor does glucuronidation use?
- Write the relation between clearance, \( k \) and \( V_d \).
- Name the phase I transformation by which a tertiary N-methyl amine loses its methyl group.
Answers
- UDP-glucuronic acid (UDPGA), with UDP-glucuronosyltransferase.
- \( \mathrm{CL} = kV_d \).
- Oxidative N-dealkylation: P450 hydroxylates the carbon α to nitrogen; the carbinolamine collapses to the secondary amine and formaldehyde.
Level 2: Part B Style
Practice Q1. A drug has \( t_{1/2} = 6.0 \) h and \( V_d = 50 \) L. Its clearance is closest to:
(a) 0.12 L h⁻¹ (b) 5.8 L h⁻¹ (c) 8.3 L h⁻¹ (d) 300 L h⁻¹
Answer: (b) 5.8 L h⁻¹
\( k = 0.693/6.0 = 0.1155 \) h⁻¹; \( \mathrm{CL} = 0.1155 \times 50 = 5.78 \) L h⁻¹. Option (c) uses \( V_d/t_{1/2} \) without \( \ln 2 \); option (d) multiplies \( V_d \) by \( t_{1/2} \).
Practice Q2. Which of the following is a phase II transformation?
(a) Aromatic hydroxylation (b) Ester hydrolysis (c) Mercapturic acid formation from an epoxide (d) N-oxidation
Answer: (c)
Mercapturic acids come from glutathione conjugation followed by processing of the tripeptide — a conjugation, hence phase II. The other three are phase I.
Practice Q3. Enalapril is converted in the body to enalaprilat, its active diacid. Enalapril is therefore:
(a) a soft drug (b) an ester prodrug (c) a mechanism-based inhibitor (d) an antimetabolite
Answer: (b)
An ester that esterases hydrolyse to release the active acid; the ester improves oral absorption of a molecule that would otherwise be too polar.
Practice Q4. A drug given intravenously (100 mg) gives AUC = 25 mg h L⁻¹; given orally (200 mg) it gives AUC = 40 mg h L⁻¹. The bioavailability is:
(a) 0.40 (b) 0.63 (c) 0.80 (d) 1.60
Answer: (c) 0.80
\( F = (40/200)/(25/100) = 0.20/0.25 = 0.80 \). Option (d) compares the AUCs without correcting for dose.
Level 3: Part C Style
Practice Q5. Plasma concentrations after a single intravenous dose of 500 mg:
| \( t \) / h | 0 (extrapolated) | 2 | 4 | 8 |
|---|---|---|---|---|
| \( C \) / mg L⁻¹ | 20.0 | 14.1 | 10.0 | 5.0 |
Which statements are correct?
- The elimination is first order with \( t_{1/2} = 4.0 \) h.
- \( V_d = 25 \) L.
- \( \mathrm{CL} \approx 4.3 \) L h⁻¹.
- After 12 h the concentration would be about 2.5 mg L⁻¹.
(a) 1, 2 and 3 only (b) 1, 2, 3 and 4 (c) 2, 3 and 4 only (d) 1 and 4 only
Answer: (b) 1, 2, 3 and 4
- 20.0 → 10.0 in 4 h, and 10.0 → 5.0 in a further 4 h; the 2 h point (14.1 = \( 20/\sqrt2 \)) confirms exponential decay. Correct.
- \( V_d = 500\ \text{mg}/20.0\ \text{mg L}^{-1} = 25 \) L. Correct.
- \( k = 0.693/4.0 = 0.173 \) h⁻¹; \( \mathrm{CL} = 0.173 \times 25 = 4.33 \) L h⁻¹. Correct.
- 12 h is three half-lives from \( t = 0 \): \( 20.0 \times (1/2)^3 = 2.5 \) mg L⁻¹. Correct.
Practice Q6. A compound is cleared almost entirely by one P450 isoform. On co-administration with a strong inhibitor of that isoform, its AUC rises fourfold with no change in \( V_d \), \( F \) or dose. Which statements are correct?
- Its clearance has fallen to one quarter of the original value.
- Its half-life has increased about fourfold.
- The steady-state concentration on an unchanged dosing regimen will rise about fourfold.
- The time needed to reach the new steady state is unchanged.
(a) 1, 2 and 3 only (b) 1 and 3 only (c) 2, 3 and 4 only (d) 1, 2, 3 and 4
Answer: (a) 1, 2 and 3 only
- \( \mathrm{AUC} = FD/\mathrm{CL} \), so a fourfold rise at constant \( F \) and \( D \) means CL fell to 25%. Correct.
- \( k = \mathrm{CL}/V_d \) falls fourfold, so \( t_{1/2} = 0.693/k \) rises fourfold. Correct.
- Steady-state concentration is proportional to \( FD/(\mathrm{CL}\tau) \). Correct.
- Time to steady state is 4–5 half-lives, and the half-life has quadrupled, so it takes about four times as long. Wrong.
Practice Q7. A lead contains (i) a para-methyl group on a phenyl ring, (ii) a methyl ester, (iii) a catechol and (iv) a tertiary N-methylamine. It is rapidly cleared. Which design changes are chemically rational responses to the likely metabolic routes?
- Replace the para-methyl by fluorine or move it, to block aromatic/benzylic oxidation at that position.
- Replace the methyl ester by an amide or a heterocyclic isostere, to resist esterases.
- Mono-methylate or otherwise mask one catechol hydroxyl, to limit O-methylation and conjugation.
- Replace the N-methyl by a longer N-alkyl chain, to prevent N-dealkylation.
(a) 1, 2 and 3 only (b) 1, 2, 3 and 4 (c) 2 and 4 only (d) 1 and 3 only
Answer: (a) 1, 2 and 3 only
- Fluorine blocks oxidation at that carbon and resists hydroxylation. Correct.
- Methyl esters are hydrolysed quickly; amides and non-hydrolysable isosteres are the standard fix. Correct.
- Catechols are substrates for catechol O-methyltransferase and for conjugation; masking a hydroxyl addresses that. Correct.
- A longer N-alkyl chain offers more carbons α to nitrogen and is generally dealkylated at least as readily; blocking requires steric or electronic protection of that position, not simple homologation. Wrong.
Quick Revision Table
| Idea | Formula / fact |
|---|---|
| Phase I | oxidation (P450), reduction, hydrolysis — introduces or unmasks a polar handle |
| P450 stoichiometry | \( \mathrm{RH + O_2 + NADPH + H^+ \to ROH + H_2O + NADP^+} \); haem-thiolate |
| Dealkylation | α-hydroxylation then collapse; gives the des-alkyl amine/phenol + carbonyl |
| Phase II donors | glucuronidation UDPGA; sulfation PAPS; GSH; acetyl-CoA; SAM; glycine |
| Bioactivation | arene oxides, quinone imines (paracetamol → NAPQI), acyl glucuronides |
| Prodrug / soft drug | activated in vivo / deactivated in vivo |
| First order | \( C = C_0e^{-kt} \); \( t_{1/2} = 0.693/k \) |
| Key relations | \( V_d = D/C_0 \); \( \mathrm{CL} = kV_d \); \( \mathrm{AUC} = FD/\mathrm{CL} \) |
| Bioavailability | \( F = (\mathrm{AUC_{oral}}/D_{\text{oral}})/(\mathrm{AUC_{iv}}/D_{\text{iv}}) \) |
| Steady state | 4–5 half-lives; loading dose \( = V_dC_{\text{target}} \); rate \( = \mathrm{CL}\,C_{\text{target}} \) |
| Saturation | Michaelis–Menten elimination: first order below \( K_M \), zero order above |
Key Takeaways
What’s Next
- Major Drug Classes and Their Chemistry: the classes whose metabolism and prodrug forms appear above.
- Drug Targets and Molecular Basis of Drug Action: what the active species does once released.
- Physicochemical Properties, SAR and QSAR: the \( \log D \) and \( pK_a \) reasoning used here.
- Medicinal Chemistry: Quick Revision.